DMN:FRA
Diamyd Medical AB
၀.၀၈၀ €
arrow_upward
+၅.၆၇%(+၀.၀၀၄၃) 1D
ဇူ ၃, GMT+၂ ၂၂:၀၀:၀၀ · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
၀.၀၈ €
High
၀.၀၈ €
Low
၀.၀၈ €
Mkt. cap
၁၆.၅၁ ကုဋေ
Avg. vol.
၁၃၃.၀၀
Volume
၀.၀၀
52-wk high
၁.၈၀ €
52-wk low
၀.၀၅ €
No. of employees
၄၄
Open
၀.၀၈ €
High
၀.၀၈ €
Low
၀.၀၈ €
Mkt. cap
၁၆.၅၁ ကုဋေ
Avg. vol.
၁၃၃.၀၀
Volume
၀.၀၀
52-wk high
၁.၈၀ €
52-wk low
၀.၀၅ €
No. of employees
၄၄
News stories
From sources across the web
MSN
·
ပြီးခဲ့သည့် ၂ မိနစ်
SK Hynix reportedly eyeing 0.5% fee rate in Nasdaq debut
Seeking Alpha
·
ပြီးခဲ့သည့် ၁၁ မိနစ်
The 1-Minute Market Report, July 4, 2026 (NYSEARCA:SPY)
Simply Wall Street
·
ပြီးခဲ့သည့် ၄၅ မိနစ်
Nasdaq (NDAQ) Is Up 7.8% After Expanding $1.5 Billion Credit Facility And Texas Launch - What's Changed
Yahoo Finance
·
ပြီးခဲ့သည့် ၄ နာရီ
2 High-Yield Dividend Stocks Just Got Kicked Out of the S&P 500. Is Either a Buy Now?
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB
AI content may include mistakes. Learn more